Although direct HER2 internalization by trastuzumab is one possible mechanism of down-modulation of HER2, these findings suggest that HER2 can be transferred from HER2+ breast tumor cells to CD14+ and CD56+ cells, which provides potential evidence for trogocytosis within the TME of HER2+ breast cancer patients. The gene discussed is CD14; the disease is breast neoplasm.